According to the agreement, Laureate will produce Alopexx’s mAb F598 antibody under cGMP conditions. This antibody is planned for use in clinical trials, and later for commercial production for the treatment and prevention of Staphylococcus aureus infections.
Daniel Vlock, president and CEO of Alopexx, said: “Laureate Pharma has a track record of demonstrated expertise in biopharmaceutical manufacturing, including capabilities in both clinical and commercial-grade materials. We look forward to our partnership with Laureate and advancing our antibody therapeutics program into the clinic.”